scorecardresearch
Eris Lifesciences acquires 100% stake in Oaknet Healthcare for Rs 650 cr

Eris Lifesciences acquires 100% stake in Oaknet Healthcare for Rs 650 cr

In a BSE filing on Wednesday, Eris Lifesciences stated that the acquisition will be done for a total consideration of Rs 650 crore. 

Oaknet Healthcare acquired/Representational image Oaknet Healthcare acquired/Representational image

Indian branded formulations manufacturing company Eris Lifesciences announced the acquisition of 100 per cent stake in Mumbai-based dermatology focused domestic formulations company Oaknet Healthcare on Tuesday. In a BSE filing on Wednesday, the company stated that the acquisition will be done for a total consideration of Rs 650 crore. 

Oaknet had a revenue base of Rs 195 crore in FY22. Eris stated in the filing that Oaknet’s dermatology and women’s health portfolio will add to their range of offerings. The company added that Eris’ Specialty Franchise will get a significant impetus with this acquisition as the company will now be present in 87 per cent of the Rs 55,000-crore chronic market with presence in cardiology, oral diabetes care, insulin, neuro/CNS and dermatology therapies. Oaknet has nearly 100 per cent presence in approximately 11,000 dermatologists with 60 per cent penetration and pan-India sales. 

Amit Bakshi, Chairman & Managing Director of Eris Lifesciences said, “As Oaknet becomes part of the Eris Group, it provides us with a robust growth platform in the areas of Dermatology and Cosmetology. In line with Strides and Zomelis acquisitions, we are confident that the Oaknet transaction will create long-term value for our shareholders.

Krishnakumar V, Executive Director & Chief Operating Officer of Eris Lifesciences said they expect to bring to bear “bear multiple value creation levers including in-house manufacturing, new product launches, expansion of field force productivity and enhancement of operational efficiency.”

Established in 2007, Eris Lifesciences is a publicly listed pharma company. Its revenues grew 3.4X in the last 10 years since FY13 and 1.6X in the last five years since FY18. Net profits also grew ~7X in the last 10 years. 

Also read: Biocon Biologics expects R&D expenses to hover between 10-15% in the next financial year